About
Technology
Issues
FAQ
Links
Official Page
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.